What we know about Coronavirus vaccines in China

Authorities approved a vaccine developed by Beijing’s Sinopharm branch on Thursday

China has advanced in the global race to develop coronavirus vaccines with most candidates in the final stages of studies earlier this year, and the first approval of a home photo for the general public came on Thursday, but without detailed efficacy data.

The following is what we know about the development of the vaccine in China, the efficacy data and the approval schedule.


Five vaccines from Sinovac Biotech, China National Pharmaceutical Group (Sinopharm), CanSinoBIO and the Chinese Academy of Sciences are in late clinical trials. None of them published detailed efficacy data.

Authorities approved a vaccine developed by the Sinopharm subsidiary in Beijing on Thursday, a day after the developer said the mid-term review of his phase 3 study showed 79.34% effectiveness, without giving details.

The efficacy reading is lower than the 86% rate for the same vaccine announced by the United Arab Emirates on December 9, based on preliminary data.

A Sinopharm executive said on Thursday that detailed data would be released later without providing a specific timetable.

Candidate Sinovac also presented various efficacy readings. Data from a late-stage study of CoronaVac photography in Turkey showed a success rate of 91.25%, while researchers in Brazil said its effectiveness was between 50% and 90%.

Brazil expects to release CoronaVac effectiveness data by January 7 after three delays.

CanSinoBIO plans to send the results of its clinical trials for its vaccine to Mexican authorities next week, a Mexican health official said.


While China has been slower than a few other countries in approving COVID-19 vaccines, it has inoculated its citizens for months with three different shots that are undergoing late-stage studies.

In July, China launched an emergency use program for essential workers and other people at high risk of infection and administered more than 4.5 million doses of the two vaccines Sinopharm and CoronaVac Sinovac.


It has intensified the program in the last month, expecting higher transmission risks during the winter.

The South China Morning Post reported that China will vaccinate up to 50 million people before the celebration of the Lunar New Year in mid-February.

China also approved a vaccine from CanSinoBIO for military use, and the vaccine was given to about 40,000 to 50,000 people, a CanSinoBIO director said on Nov. 28.


Sinopharm and Sinovac vaccines are based on traditional technology that uses inactivated or dead virus, which cannot replicate in human cells, to trigger an immune response.

The overall rate of adverse reactions to these COVID-19 vaccines is similar to that of other inactivated vaccines, and the rate of occurrence of relatively serious side effects, such as allergies, is about two in a million, the administration official said on Thursday. National Health, Zeng Yixin. .


The United Arab Emirates has become the first country to publicly launch a Chinese vaccine this month.

Pakistan on Thursday announced a 1.2 million-dose purchase agreement with Sinopharm.

Sinovac’s CoronaVac image was signed by Brazil, Indonesia, Turkey, Chile and Singapore. The company is also in supply talks with Malaysia and the Philippines.

CanSinoBIO has a supply contract with Mexico.

(Except for the title, this story was not edited by NDTV staff and is published in a syndicated stream.)